AI Image
Popular GLP-1 weight loss drugs linked to potential effects on brain health
Yahoo Health • • health
Key Points:
- Ground-breaking obesity drugs like semaglutide and tirzepatide have shown potential not only for weight loss and cardiometabolic health improvements but also for possibly protecting brain health, according to a new review in Science.
- These drugs mimic hormones (GLP-1 and GIP) and are linked through observational studies and animal research to reduced risks of cognitive impairment and dementia, though causation has not been established.
- Clinical trials, such as Novo Nordisk's EVOKE studies on semaglutide in early Alzheimer's patients, showed biomarker improvements but no slowing of disease progression, highlighting a gap between biological effects and clinical outcomes.
- Researchers suggest these medications may be more effective at preserving cognitive function if used early in people with obesity or Type 2 diabetes before significant brain damage occurs, rather than reversing neurodegenerative diseases.
- Experts caution that while the evidence is promising, brain protection alone is not yet a reason to start these drugs, and any cognitive benefits remain uncertain for patients without existing metabolic conditions.
![If you bought an iPhone Duo, have you kept or returned it? [Poll]](https://media-cdn.cashwalklabs.io/https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fimages.cashwalklabs.io%2F0_admin%2Fnews-ai-images%2F01a1cb91-fbfd-752c-9444-39f022e668ff.webp?format=webp&w=120&h=80)
